Latest Headlines

Latest Headlines

Affiris clears Phase I with Parkinson's vaccine candidate

Austria-based vaccinemaker Affiris announced that its Parkinson's disease vaccine has met its primary endpoint in a small Phase I safety trial of patients receiving two different doses of the jab.

Michael J. Fox Foundation bankrolls AFFiRiS Parkinson's vaccine

The Michael J. Fox Foundation (MJFF) will supply $1.5 million for an early clinical study of Affitope PD01, a vaccine being developed by Vienna, Austria-based AFFiRiS for the treatment of Parkinson's

AFFiRiS readies Alzheimer's vax for PhII study

Austria's AFFiRiS AG is moving its lead Alzheimer's vaccine into a Phase II study that will test just how valuable the GlaxoSmithKline-partnered therapy is against a primary target in the fight